Physician profile
Jay J Burlingame
NPI 1336110808
$4,729.29
in general payments reported to CMS, 2019-2025
19 companies · $456 in 2025
The $456 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,314 · 2020: $344 · 2021: $307 · 2022: $1,751 · 2023: $380 · 2024: $178 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,466.20 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $652.69 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $530.07 | 2022-2025 | Infuse, Scoutpro Osmolarity System, Xiidra |
| Johnson & Johnson Vision Care, INC. | $384.78 | 2019-2025 | Acuvue |
| Coopervision INC. | $327.37 | 2019-2024 | Myday Contact Lens, Clariti Contact Lens |
| Oyster Point Pharma, INC. | $178.30 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $172.68 | 2019-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $153.27 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $149.91 | 2019-2021 | |
| Allergan, INC. | $146.54 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $138.72 | 2019 | |
| Dompe US, INC. | $117.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $88.51 | 2020-2022 | |
| Genzyme Corporation | $83.93 | 2019 | |
| Shire North American Group INC | $41.67 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $34.40 | 2019 | |
| Menicon America INC | $27.17 | 2019 | |
| Lumenis, INC | $24.28 | 2021 | |
| Alcon Research LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Burlingame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.